Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market entry ...

Opdivo carries a very high cost in the US – $12,500 a month or $150,000 for patients who stay on the drug for a year, but BMS is likely to offer the drug at a discount on this level in Europe ...

Among patients with advanced melanoma, treatment with Opdivo (nivolumab) with or without Yervoy (ipilimumab) benefited both overall survival (OS, the time a patient lives, regardless of disease status ...

The agency has already approved Keytruda and Opdivo when combined with chemotherapy as a first-line treatment for patients with HER2-negative unresectable or metastatic gastric or gastroesophageal ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

The most notable change is to the company’s logo: what was previously a sans-serif wordmark styled as “Moz://a” has been updated to correctly spell out the Mozilla name, featuring a new ...

What makes a good AI logo? It’s a thorny question that every player in the current crop of leading AI companies has faced, since unlike an email app — which marries neatly with an envelope ...

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo. A treatment combination with Yervoy (ipilimumab) plus ...

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash. The ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...